Centralised versus decentralised manufacturing and the delivery of healthcare products: A United Kingdom exemplar

Background. The cell and gene therapy (CGT) field is at a critical juncture. Clinical successes have underpinned the requirement for developing manufacturing capacity suited to patient-specific therapies that can satisfy the eventual demand post-launch. Decentralised or ‘redistributed’ manufacturing...

Full description

Bibliographic Details

Main Authors:	Richard P. Harrison, Qasim A. Rafiq, Nick Medcalf
Format:	Default Article
Published:	2018
Subjects:	Mechanical engineering not elsewhere classified Advanced manufacturing technology Cell and gene therapy Cost of goods Decentralised manufacturing Organisational change Quality control Mechanical Engineering not elsewhere classified
Online Access:	https://hdl.handle.net/2134/34023
Tags:	Add Tag No Tags, Be the first to tag this record!